The Technical Analyst
Provention Bio Inc [PRVB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Provention Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $24.98
America/New_York / 26 apr 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 2 375.42 mill |
| EPS: | -1.520 |
| P/E: | -16.43 |
| Earnings Date: | Aug 02, 2023 |
| SharesOutstanding: | 95.09 mill |
| Avg Daily Volume: | 2.84 mill |
| RATING 2023-04-27 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -16.43 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -2.80x |
| Company: PE -16.43 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 24.39 - 25.57 ( +/- 2.38%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-04-27 | Sessa Capital (master), L.p. | Sell | 15 567 497 | Common Stock |
| 2023-04-27 | Wysenski Nancy | Sell | 128 981 | Option to Purchase Common Stock |
| 2023-04-27 | Wysenski Nancy | Sell | 22 200 | Option to Purchase Common Stock |
| 2023-04-27 | Wysenski Nancy | Sell | 23 000 | Option to Purchase Common Stock |
| 2023-04-27 | Wysenski Nancy | Sell | 33 000 | Option to Purchase Common Stock |
| INSIDER POWER |
|---|
| -62.73 |
| Last 100 transactions |
| Buy: 11 373 023 | Sell: 48 540 195 |
Forecast:
01:40 - $23.75
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.98 (0.00% ) |
| Volume | 9.12 mill |
| Avg. Vol. | 2.84 mill |
| % of Avg. Vol | 320.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRVB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PRVB
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Latest Press Releases
2023-04-26 02:00:00 - Press Release
Press Release: Hart-scott-rodino Waiting Period Expires For Sanofi's Acquisition Of Provention Bio, Inc.
Hart-scott- rodino waiting period expires for sanofi's acquisition of provention bio, inc. paris, france – april 26 , 2023 – sanofi announced today that the waiting period under the hart-scott-rodino antitrust improvements act of 1976, as amended (the “hsr act”), applicable to sanofi's proposed acquisition of provention bio, inc. (“provention bio”, nasdaq: prvb) has expired. on march 24, 2023, sanofi commenced a cash tender offer (the “offer”) to purchase all outstanding shares of common stock of provention bio (the “shares”), for $25.00 per share, to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law.
2023-03-29 14:58:00 - Press Release
Provention Bio Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Provention Bio, Inc. - Prvb
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of provention bio, inc. (nasdaqgs: prvb) to sanofi (nasdaqgs: sny). under the terms of the proposed transaction, shareholders of provention will receive only $25.00 in cash for each share of provention that they own.
2023-03-14 03:32:00 - Press Release
Shareholder Alert: The M&a Class Action Firm Announces The Investigation Of Provention Bio, Inc. - Prvb
New york , march 14, 2023 /prnewswire/ -- juan monteverde , founder and managing partner of the class action firm monteverde & associates pc (the "m&a class action firm"), a national securities firm rated top 50 in the 2018-2021 iss securities class action services report and headquartered at the empire state building in new york city, is investigating provention bio, inc. (nasdaq: prvb), relating to its proposed sale to sanofi. under the terms of the agreement prvb shareholders are expected to receive $25.00 in cash per share they own.
2023-03-13 12:42:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Provention Bio, Inc. Has Obtained A Fair Price In Its Transaction With Sanofi
Milwaukee , march 13, 2023 /prnewswire/ -- ademi llp is investigating provention bio (nasdaq: prvb) for possible breaches of fiduciary duty and other violations of law in its transaction with sanofi. click here to learn how to join the action https://www.ademilaw.com/case/provention-bio-inc or call guri ademi toll-free at 866-264-3995.
2023-03-13 09:17:00 - Press Release
Prvb Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Provention Bio, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of provention bio, inc. (nasdaq: prvb) to sanofi for $25.00 per share in cash is fair to provention shareholders. halper sadeh encourages provention shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Latest News
2023-04-10 22:58:48 - 24/7 Wall Street
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
2023-03-16 16:56:47 - The Motley Fool
Why Provention Bio Stock Skyrocketed 256% This Week
Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.
2023-03-14 13:44:05 - Zacks Investment Research
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
2023-03-13 20:22:57 - Invezz
This biopharma stock jumped over 250% on Monday: what happened?
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
2023-03-13 19:15:00 - The Motley Fool
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.
2023-03-13 11:17:00 - Market Watch
Regional banks pace decliners, as biotech deals lift Seagen and Provention Bio
Here are some of the biggest movers on Monday with banks firmly in focus after federal regulators stepped into protect deposits at fallen bank SVB.
2023-03-13 10:15:02 - Proactive Investors
Provention Bio shares soar after Sanofi agrees to buy company in $2.9B cash deal
French drugmaker Sanofi has announced an agreement to acquire US-based biopharmaceutical company Provention Bio Inc (NASDAQ:PRVB), which focuses on autoimmune diseases, for $25 per share in cash, or a total equity value of about $2.9 billion. Provention Bio's stock surged more than 250% in early trading on Monday, while shares of Sanofi slipped 1%.
2023-03-13 08:13:19 - InvestorPlace
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Provention Bio (NASDAQ: PRVB ) stock is rocketing higher on Monday following news that Sanofi (NASDAQ: SNY ) is acquiring the company. That deal has Sanofi agreeing to acquire Provention Bio for $25 per share in cash.
2023-03-13 07:00:00 - PRNewsWire
Provention Bio Cancels Fourth Quarter and Full Year 2022 Earnings Release and Conference Call
RED BANK, N.J. , March 13, 2023 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi, Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions.
2023-03-13 06:43:18 - Pulse2
Sanofi To Buy Provention Bio In $2.9 Billion Deal (SNY) (PRVB)
Sanofi (NASDAQ: SNY) announced it is buying Provention Bio (NASDAQ: PRVB) as part of a $2.9 billion deal. These are the details.